This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kavatha, D.
Right arrow Articles by Koratzanis, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kavatha, D.
Right arrow Articles by Koratzanis, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2003, p. 897-900, Vol. 47, No. 3
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.3.897-900.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Cefpodoxime-Proxetil versus Trimethoprim-Sulfamethoxazole for Short-Term Therapy of Uncomplicated Acute Cystitis in Women

Demetra Kavatha,1 Helen Giamarellou,2* Zoe Alexiou,1 Nickolas Vlachogiannis,3 Stavroula Pentea,1 Thomas Gozadinos,4 Garyphalia Poulakou,1 Agissilaos Hatzipapas,1 and George Koratzanis2

1st Department of Propedeutic Medicine,"Laiko" General Hospital,1 4th Department of Propedeutic Medicine, "Sismanoglio" General Hospital, Athens Medical School, Athens,2 Primary Health Centre of Lavrion, Attica,3 Halkida General Hospital, Evia, Greece4

Received 30 July 2002/ Returned for modification 18 September 2002/ Accepted 21 November 2002

One hundred sixty-three women with uncomplicated acute lower urinary tract infections were included in a multicenter randomized study comparing cefpodoxime-proxetil (one 100-mg tablet twice daily) with trimethoprim-sulfamethoxazole (one double-strength tablet [160/800 mg] twice daily) for 3 days. A total of 30 women in both arms were excluded from the study for various reasons. At 4 to 7 days after the discontinuation of therapy, 62 of 63 (98.4%) cefpodoxime-proxetil recipients and 70 of 70 (100%) trimethoprim-sulfamethoxazole patients were clinically cured and demonstrated bacteriological eradication, respectively. At 28 days after treatment, 48 of 55 (87.3%) and 43 of 50 (86%) cefpodoxime-proxetil recipients as well as 51 of 60 (85%) and 42 of 50 (84%) trimethoprim-sulfamethoxazole recipients were clinically cured and demonstrated bacteriological eradication, respectively. Independently of the prescribed regimen, a significant difference (P < 0.001) in failure rates was observed only for patients with a previous history of three or more episodes of acute cystitis per year. With the exception of one patient in the trimethoprim-sulfamethoxazole arm who discontinued therapy because of gastrointestinal pain, both antimicrobials were well tolerated. In conclusion, cefpodoxime-proxetil treatment for 3 days was as safe and effective as trimethoprim-sulfamethoxazole for 3 days for the treatment of uncomplicated acute cystitis in women.

* Corrresponding author. Mailing address: 4th Department of Internal Medicine, Sismanoglio Hospital, 151 26 Maroussi-Attikis, Greece. Phone: 30210-8033817. Fax: 30210-8039543. E-mail: hgiama{at}ath.forthnet.gr.

Antimicrobial Agents and Chemotherapy, March 2003, p. 897-900, Vol. 47, No. 3
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.3.897-900.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»